Use of treatments among patients with extensive stage small-cell lung cancer in the MDV and DeSC cohorts, by line of therapy and time period before and after approval of first-line anti-PD-L1 therapy.
| . | MDV cohort . | DeSC cohort . | ||||
|---|---|---|---|---|---|---|
| . | Overall n (%) . | ≤2019 n (%) . | ≥2020 n (%) . | Overall n (%) . | ≤2019 n (%) . | ≥2020 n (%) . |
| 1 L | ||||||
| N | 6302 | 3482 | 2820 | 903 | 436 | 467 |
| Platinum + Etoposide + no PD-L1 | 4411 (70.0) | 2609 (74.9) | 1802 (63.9) | 532 (58.9) | 339 (77.8) | 193 (41.3) |
| Platinum + Etoposide + PD-L1 | 818 (13.0) | 1 (0.0) | 817 (29.0) | 264 (29.2) | 18 (4.1) | 246 (52.7) |
| Platinum + Irinotecan | 705 (11.2) | 641 (18.4) | 64 (2.3) | 63 (7.0) | 56 (12.8) | 7 (1.5) |
| Amrubicin monotherapy | 127 (2.0) | 83 (2.4) | 44 (2.3) | 4 (0.4) | 1 (0.2) | 3 (0.6) |
| Topotecan monotherapy | 12 (0.2) | 10 (0.3) | 2 (0.1) | 2 (0.2) | 2 (0.5) | – |
| Taxane monotherapy | 9 (0.1) | 7 (0.2) | 2 (0.1) | 1 (0.1) | 1 (0.2) | – |
| Other single-agent chemotherapy | 109 (1.7) | 62 (1.8) | 47 (1.7) | 6 (0.7) | 4 (0.9) | 2 (0.4) |
| All other regimens | 111 (1.8) | 69 (2.0) | 42 (1.6) | 31 (3.4) | 15 (3.4) | 16 (3.4) |
| 2 L | ||||||
| N | 3241 | 2027 | 1214 | 454 | 175 | 279 |
| Platinum + Etoposide + no PD-L1 | 384 (11.9) | 293 (14.5) | 91 (7.5) | 36 (7.9) | 23 (13.1) | 13 (4.7) |
| Platinum + Etoposide + PD-L1 | 181 (5.6) | 55 (2.7) | 126 (10.4) | 17 (3.7) | 3 (1.7) | 14 (5.0) |
| Platinum + Irinotecan | 175 (5.4) | 130 (6.4) | 45 (3.7) | 7 (1.5) | 4 (2.3) | 3 (1.1) |
| Amrubicin monotherapy | 1934 (59.7) | 1202 (59.3) | 732 (60.3) | 312 (68.7) | 108 (61.7) | 204 (73.1) |
| Topotecan monotherapy | 206 (6.4) | 123 (6.1) | 83 (6.8) | 21 (4.6) | 5 (2.9) | 16 (5.7) |
| Taxane monotherapy | 56 (1.7) | 31 (1.5) | 25 (2.1) | 13 (2.9) | 4 (2.3) | 9 (3.2) |
| Other single-agent chemotherapy | 144 (4.4) | 105 (5.2) | 39 (3.2) | 20 (4.4) | 12 (6.9) | 8 (2.9) |
| All other regimens | 161 (5.0) | 88 (4.4) | 73 (6.0) | 28 (6.2) | 16 (9.1) | 12 (4.3) |
| 3 L | ||||||
| N | 1480 | 1013 | 467 | 193 | 72 | 121 |
| Platinum + Etoposide + no PD-L1 | 197 (13.3) | 147 (14.5) | 50 (10.7) | 19 (9.8) | 9 (12.5) | 10 (8.3) |
| Platinum + Etoposide + PD-L1 | 53 (3.6) | 40 (4.0) | 13 (2.8) | 2 (1.0) | 2 (2.8) | – |
| Platinum + Irinotecan | 123 (8.3) | 75 (7.4) | 48 (10.3) | 19 (9.8) | 5 (6.9) | 14 (11.6) |
| Amrubicin monotherapy | 437 (29.5) | 317 (31.3) | 120 (25.8) | 43 (22.3) | 19 (26.4) | 24 (19.8) |
| Topotecan monotherapy | 230 (15.5) | 146 (14.4) | 84 (18.0) | 28 (14.5) | 6 (8.3) | 22 (18.2) |
| Taxane monotherapy | 29 (6.1) | 21 (2.1) | 8 (1.7) | 11 (5.7) | 6 (8.3) | 5 (4.1) |
| Other single-agent chemotherapy | 321 (21.7) | 206 (20.3) | 115 (24.6) | 60 (31.1) | 20 (27.8) | 40 (33.1) |
| All other regimens | 90 (6.1) | 61 (6.0) | 29 (6.2) | 11 (5.7) | 5 (6.9) | 6 (5.0) |
| 4 L | ||||||
| N | 602 | 437 | 165 | 70 | 24 | 46 |
| Platinum + Etoposide + no PD-L1 | 86 (14.3) | 56 (12.8) | 30 (18.2) | 9 (12.9) | 2 (8.3) | 7 (15.2) |
| Platinum + Etoposide + PD-L1 | 16 (2.7) | 14 (3.2) | 2 (1.2) | 0 (0.0) | – | – |
| Platinum + Irinotecan | 41 (6.8) | 32 (7.3) | 9 (5.5) | 2 (2.9) | 1 (4.2) | 1 (2.2) |
| Amrubicin monotherapy | 91 (15.1) | 68 (15.6) | 23 (13.9) | 7 (10.0) | 1 (4.2) | 6 (13.0) |
| Topotecan monotherapy | 160 (26.6) | 117 (26.8) | 43 (26.1) | 19 (27.1) | 7 (29.2) | 12 (26.1) |
| Taxane monotherapy | 35 (5.8) | 23 (5.3) | 12 (7.3) | 12 (17.1) | 4 (16.7) | 8 (17.4) |
| Other single-agent chemotherapy | 108 (17.9) | 78 (17.9) | 30 (18.2) | 16 (22.9) | 7 (29.2) | 9 (19.6) |
| All other regimens | 65 (10.8) | 49 (11.2) | 165 (9.7) | 5 (7.1) | 2 (8.3) | 3 (6.5) |
| . | MDV cohort . | DeSC cohort . | ||||
|---|---|---|---|---|---|---|
| . | Overall n (%) . | ≤2019 n (%) . | ≥2020 n (%) . | Overall n (%) . | ≤2019 n (%) . | ≥2020 n (%) . |
| 1 L | ||||||
| N | 6302 | 3482 | 2820 | 903 | 436 | 467 |
| Platinum + Etoposide + no PD-L1 | 4411 (70.0) | 2609 (74.9) | 1802 (63.9) | 532 (58.9) | 339 (77.8) | 193 (41.3) |
| Platinum + Etoposide + PD-L1 | 818 (13.0) | 1 (0.0) | 817 (29.0) | 264 (29.2) | 18 (4.1) | 246 (52.7) |
| Platinum + Irinotecan | 705 (11.2) | 641 (18.4) | 64 (2.3) | 63 (7.0) | 56 (12.8) | 7 (1.5) |
| Amrubicin monotherapy | 127 (2.0) | 83 (2.4) | 44 (2.3) | 4 (0.4) | 1 (0.2) | 3 (0.6) |
| Topotecan monotherapy | 12 (0.2) | 10 (0.3) | 2 (0.1) | 2 (0.2) | 2 (0.5) | – |
| Taxane monotherapy | 9 (0.1) | 7 (0.2) | 2 (0.1) | 1 (0.1) | 1 (0.2) | – |
| Other single-agent chemotherapy | 109 (1.7) | 62 (1.8) | 47 (1.7) | 6 (0.7) | 4 (0.9) | 2 (0.4) |
| All other regimens | 111 (1.8) | 69 (2.0) | 42 (1.6) | 31 (3.4) | 15 (3.4) | 16 (3.4) |
| 2 L | ||||||
| N | 3241 | 2027 | 1214 | 454 | 175 | 279 |
| Platinum + Etoposide + no PD-L1 | 384 (11.9) | 293 (14.5) | 91 (7.5) | 36 (7.9) | 23 (13.1) | 13 (4.7) |
| Platinum + Etoposide + PD-L1 | 181 (5.6) | 55 (2.7) | 126 (10.4) | 17 (3.7) | 3 (1.7) | 14 (5.0) |
| Platinum + Irinotecan | 175 (5.4) | 130 (6.4) | 45 (3.7) | 7 (1.5) | 4 (2.3) | 3 (1.1) |
| Amrubicin monotherapy | 1934 (59.7) | 1202 (59.3) | 732 (60.3) | 312 (68.7) | 108 (61.7) | 204 (73.1) |
| Topotecan monotherapy | 206 (6.4) | 123 (6.1) | 83 (6.8) | 21 (4.6) | 5 (2.9) | 16 (5.7) |
| Taxane monotherapy | 56 (1.7) | 31 (1.5) | 25 (2.1) | 13 (2.9) | 4 (2.3) | 9 (3.2) |
| Other single-agent chemotherapy | 144 (4.4) | 105 (5.2) | 39 (3.2) | 20 (4.4) | 12 (6.9) | 8 (2.9) |
| All other regimens | 161 (5.0) | 88 (4.4) | 73 (6.0) | 28 (6.2) | 16 (9.1) | 12 (4.3) |
| 3 L | ||||||
| N | 1480 | 1013 | 467 | 193 | 72 | 121 |
| Platinum + Etoposide + no PD-L1 | 197 (13.3) | 147 (14.5) | 50 (10.7) | 19 (9.8) | 9 (12.5) | 10 (8.3) |
| Platinum + Etoposide + PD-L1 | 53 (3.6) | 40 (4.0) | 13 (2.8) | 2 (1.0) | 2 (2.8) | – |
| Platinum + Irinotecan | 123 (8.3) | 75 (7.4) | 48 (10.3) | 19 (9.8) | 5 (6.9) | 14 (11.6) |
| Amrubicin monotherapy | 437 (29.5) | 317 (31.3) | 120 (25.8) | 43 (22.3) | 19 (26.4) | 24 (19.8) |
| Topotecan monotherapy | 230 (15.5) | 146 (14.4) | 84 (18.0) | 28 (14.5) | 6 (8.3) | 22 (18.2) |
| Taxane monotherapy | 29 (6.1) | 21 (2.1) | 8 (1.7) | 11 (5.7) | 6 (8.3) | 5 (4.1) |
| Other single-agent chemotherapy | 321 (21.7) | 206 (20.3) | 115 (24.6) | 60 (31.1) | 20 (27.8) | 40 (33.1) |
| All other regimens | 90 (6.1) | 61 (6.0) | 29 (6.2) | 11 (5.7) | 5 (6.9) | 6 (5.0) |
| 4 L | ||||||
| N | 602 | 437 | 165 | 70 | 24 | 46 |
| Platinum + Etoposide + no PD-L1 | 86 (14.3) | 56 (12.8) | 30 (18.2) | 9 (12.9) | 2 (8.3) | 7 (15.2) |
| Platinum + Etoposide + PD-L1 | 16 (2.7) | 14 (3.2) | 2 (1.2) | 0 (0.0) | – | – |
| Platinum + Irinotecan | 41 (6.8) | 32 (7.3) | 9 (5.5) | 2 (2.9) | 1 (4.2) | 1 (2.2) |
| Amrubicin monotherapy | 91 (15.1) | 68 (15.6) | 23 (13.9) | 7 (10.0) | 1 (4.2) | 6 (13.0) |
| Topotecan monotherapy | 160 (26.6) | 117 (26.8) | 43 (26.1) | 19 (27.1) | 7 (29.2) | 12 (26.1) |
| Taxane monotherapy | 35 (5.8) | 23 (5.3) | 12 (7.3) | 12 (17.1) | 4 (16.7) | 8 (17.4) |
| Other single-agent chemotherapy | 108 (17.9) | 78 (17.9) | 30 (18.2) | 16 (22.9) | 7 (29.2) | 9 (19.6) |
| All other regimens | 65 (10.8) | 49 (11.2) | 165 (9.7) | 5 (7.1) | 2 (8.3) | 3 (6.5) |
1 L, first line; 2 L, second line; 3 L, third line; 4 L, fourth line.
Use of treatments among patients with extensive stage small-cell lung cancer in the MDV and DeSC cohorts, by line of therapy and time period before and after approval of first-line anti-PD-L1 therapy.
| . | MDV cohort . | DeSC cohort . | ||||
|---|---|---|---|---|---|---|
| . | Overall n (%) . | ≤2019 n (%) . | ≥2020 n (%) . | Overall n (%) . | ≤2019 n (%) . | ≥2020 n (%) . |
| 1 L | ||||||
| N | 6302 | 3482 | 2820 | 903 | 436 | 467 |
| Platinum + Etoposide + no PD-L1 | 4411 (70.0) | 2609 (74.9) | 1802 (63.9) | 532 (58.9) | 339 (77.8) | 193 (41.3) |
| Platinum + Etoposide + PD-L1 | 818 (13.0) | 1 (0.0) | 817 (29.0) | 264 (29.2) | 18 (4.1) | 246 (52.7) |
| Platinum + Irinotecan | 705 (11.2) | 641 (18.4) | 64 (2.3) | 63 (7.0) | 56 (12.8) | 7 (1.5) |
| Amrubicin monotherapy | 127 (2.0) | 83 (2.4) | 44 (2.3) | 4 (0.4) | 1 (0.2) | 3 (0.6) |
| Topotecan monotherapy | 12 (0.2) | 10 (0.3) | 2 (0.1) | 2 (0.2) | 2 (0.5) | – |
| Taxane monotherapy | 9 (0.1) | 7 (0.2) | 2 (0.1) | 1 (0.1) | 1 (0.2) | – |
| Other single-agent chemotherapy | 109 (1.7) | 62 (1.8) | 47 (1.7) | 6 (0.7) | 4 (0.9) | 2 (0.4) |
| All other regimens | 111 (1.8) | 69 (2.0) | 42 (1.6) | 31 (3.4) | 15 (3.4) | 16 (3.4) |
| 2 L | ||||||
| N | 3241 | 2027 | 1214 | 454 | 175 | 279 |
| Platinum + Etoposide + no PD-L1 | 384 (11.9) | 293 (14.5) | 91 (7.5) | 36 (7.9) | 23 (13.1) | 13 (4.7) |
| Platinum + Etoposide + PD-L1 | 181 (5.6) | 55 (2.7) | 126 (10.4) | 17 (3.7) | 3 (1.7) | 14 (5.0) |
| Platinum + Irinotecan | 175 (5.4) | 130 (6.4) | 45 (3.7) | 7 (1.5) | 4 (2.3) | 3 (1.1) |
| Amrubicin monotherapy | 1934 (59.7) | 1202 (59.3) | 732 (60.3) | 312 (68.7) | 108 (61.7) | 204 (73.1) |
| Topotecan monotherapy | 206 (6.4) | 123 (6.1) | 83 (6.8) | 21 (4.6) | 5 (2.9) | 16 (5.7) |
| Taxane monotherapy | 56 (1.7) | 31 (1.5) | 25 (2.1) | 13 (2.9) | 4 (2.3) | 9 (3.2) |
| Other single-agent chemotherapy | 144 (4.4) | 105 (5.2) | 39 (3.2) | 20 (4.4) | 12 (6.9) | 8 (2.9) |
| All other regimens | 161 (5.0) | 88 (4.4) | 73 (6.0) | 28 (6.2) | 16 (9.1) | 12 (4.3) |
| 3 L | ||||||
| N | 1480 | 1013 | 467 | 193 | 72 | 121 |
| Platinum + Etoposide + no PD-L1 | 197 (13.3) | 147 (14.5) | 50 (10.7) | 19 (9.8) | 9 (12.5) | 10 (8.3) |
| Platinum + Etoposide + PD-L1 | 53 (3.6) | 40 (4.0) | 13 (2.8) | 2 (1.0) | 2 (2.8) | – |
| Platinum + Irinotecan | 123 (8.3) | 75 (7.4) | 48 (10.3) | 19 (9.8) | 5 (6.9) | 14 (11.6) |
| Amrubicin monotherapy | 437 (29.5) | 317 (31.3) | 120 (25.8) | 43 (22.3) | 19 (26.4) | 24 (19.8) |
| Topotecan monotherapy | 230 (15.5) | 146 (14.4) | 84 (18.0) | 28 (14.5) | 6 (8.3) | 22 (18.2) |
| Taxane monotherapy | 29 (6.1) | 21 (2.1) | 8 (1.7) | 11 (5.7) | 6 (8.3) | 5 (4.1) |
| Other single-agent chemotherapy | 321 (21.7) | 206 (20.3) | 115 (24.6) | 60 (31.1) | 20 (27.8) | 40 (33.1) |
| All other regimens | 90 (6.1) | 61 (6.0) | 29 (6.2) | 11 (5.7) | 5 (6.9) | 6 (5.0) |
| 4 L | ||||||
| N | 602 | 437 | 165 | 70 | 24 | 46 |
| Platinum + Etoposide + no PD-L1 | 86 (14.3) | 56 (12.8) | 30 (18.2) | 9 (12.9) | 2 (8.3) | 7 (15.2) |
| Platinum + Etoposide + PD-L1 | 16 (2.7) | 14 (3.2) | 2 (1.2) | 0 (0.0) | – | – |
| Platinum + Irinotecan | 41 (6.8) | 32 (7.3) | 9 (5.5) | 2 (2.9) | 1 (4.2) | 1 (2.2) |
| Amrubicin monotherapy | 91 (15.1) | 68 (15.6) | 23 (13.9) | 7 (10.0) | 1 (4.2) | 6 (13.0) |
| Topotecan monotherapy | 160 (26.6) | 117 (26.8) | 43 (26.1) | 19 (27.1) | 7 (29.2) | 12 (26.1) |
| Taxane monotherapy | 35 (5.8) | 23 (5.3) | 12 (7.3) | 12 (17.1) | 4 (16.7) | 8 (17.4) |
| Other single-agent chemotherapy | 108 (17.9) | 78 (17.9) | 30 (18.2) | 16 (22.9) | 7 (29.2) | 9 (19.6) |
| All other regimens | 65 (10.8) | 49 (11.2) | 165 (9.7) | 5 (7.1) | 2 (8.3) | 3 (6.5) |
| . | MDV cohort . | DeSC cohort . | ||||
|---|---|---|---|---|---|---|
| . | Overall n (%) . | ≤2019 n (%) . | ≥2020 n (%) . | Overall n (%) . | ≤2019 n (%) . | ≥2020 n (%) . |
| 1 L | ||||||
| N | 6302 | 3482 | 2820 | 903 | 436 | 467 |
| Platinum + Etoposide + no PD-L1 | 4411 (70.0) | 2609 (74.9) | 1802 (63.9) | 532 (58.9) | 339 (77.8) | 193 (41.3) |
| Platinum + Etoposide + PD-L1 | 818 (13.0) | 1 (0.0) | 817 (29.0) | 264 (29.2) | 18 (4.1) | 246 (52.7) |
| Platinum + Irinotecan | 705 (11.2) | 641 (18.4) | 64 (2.3) | 63 (7.0) | 56 (12.8) | 7 (1.5) |
| Amrubicin monotherapy | 127 (2.0) | 83 (2.4) | 44 (2.3) | 4 (0.4) | 1 (0.2) | 3 (0.6) |
| Topotecan monotherapy | 12 (0.2) | 10 (0.3) | 2 (0.1) | 2 (0.2) | 2 (0.5) | – |
| Taxane monotherapy | 9 (0.1) | 7 (0.2) | 2 (0.1) | 1 (0.1) | 1 (0.2) | – |
| Other single-agent chemotherapy | 109 (1.7) | 62 (1.8) | 47 (1.7) | 6 (0.7) | 4 (0.9) | 2 (0.4) |
| All other regimens | 111 (1.8) | 69 (2.0) | 42 (1.6) | 31 (3.4) | 15 (3.4) | 16 (3.4) |
| 2 L | ||||||
| N | 3241 | 2027 | 1214 | 454 | 175 | 279 |
| Platinum + Etoposide + no PD-L1 | 384 (11.9) | 293 (14.5) | 91 (7.5) | 36 (7.9) | 23 (13.1) | 13 (4.7) |
| Platinum + Etoposide + PD-L1 | 181 (5.6) | 55 (2.7) | 126 (10.4) | 17 (3.7) | 3 (1.7) | 14 (5.0) |
| Platinum + Irinotecan | 175 (5.4) | 130 (6.4) | 45 (3.7) | 7 (1.5) | 4 (2.3) | 3 (1.1) |
| Amrubicin monotherapy | 1934 (59.7) | 1202 (59.3) | 732 (60.3) | 312 (68.7) | 108 (61.7) | 204 (73.1) |
| Topotecan monotherapy | 206 (6.4) | 123 (6.1) | 83 (6.8) | 21 (4.6) | 5 (2.9) | 16 (5.7) |
| Taxane monotherapy | 56 (1.7) | 31 (1.5) | 25 (2.1) | 13 (2.9) | 4 (2.3) | 9 (3.2) |
| Other single-agent chemotherapy | 144 (4.4) | 105 (5.2) | 39 (3.2) | 20 (4.4) | 12 (6.9) | 8 (2.9) |
| All other regimens | 161 (5.0) | 88 (4.4) | 73 (6.0) | 28 (6.2) | 16 (9.1) | 12 (4.3) |
| 3 L | ||||||
| N | 1480 | 1013 | 467 | 193 | 72 | 121 |
| Platinum + Etoposide + no PD-L1 | 197 (13.3) | 147 (14.5) | 50 (10.7) | 19 (9.8) | 9 (12.5) | 10 (8.3) |
| Platinum + Etoposide + PD-L1 | 53 (3.6) | 40 (4.0) | 13 (2.8) | 2 (1.0) | 2 (2.8) | – |
| Platinum + Irinotecan | 123 (8.3) | 75 (7.4) | 48 (10.3) | 19 (9.8) | 5 (6.9) | 14 (11.6) |
| Amrubicin monotherapy | 437 (29.5) | 317 (31.3) | 120 (25.8) | 43 (22.3) | 19 (26.4) | 24 (19.8) |
| Topotecan monotherapy | 230 (15.5) | 146 (14.4) | 84 (18.0) | 28 (14.5) | 6 (8.3) | 22 (18.2) |
| Taxane monotherapy | 29 (6.1) | 21 (2.1) | 8 (1.7) | 11 (5.7) | 6 (8.3) | 5 (4.1) |
| Other single-agent chemotherapy | 321 (21.7) | 206 (20.3) | 115 (24.6) | 60 (31.1) | 20 (27.8) | 40 (33.1) |
| All other regimens | 90 (6.1) | 61 (6.0) | 29 (6.2) | 11 (5.7) | 5 (6.9) | 6 (5.0) |
| 4 L | ||||||
| N | 602 | 437 | 165 | 70 | 24 | 46 |
| Platinum + Etoposide + no PD-L1 | 86 (14.3) | 56 (12.8) | 30 (18.2) | 9 (12.9) | 2 (8.3) | 7 (15.2) |
| Platinum + Etoposide + PD-L1 | 16 (2.7) | 14 (3.2) | 2 (1.2) | 0 (0.0) | – | – |
| Platinum + Irinotecan | 41 (6.8) | 32 (7.3) | 9 (5.5) | 2 (2.9) | 1 (4.2) | 1 (2.2) |
| Amrubicin monotherapy | 91 (15.1) | 68 (15.6) | 23 (13.9) | 7 (10.0) | 1 (4.2) | 6 (13.0) |
| Topotecan monotherapy | 160 (26.6) | 117 (26.8) | 43 (26.1) | 19 (27.1) | 7 (29.2) | 12 (26.1) |
| Taxane monotherapy | 35 (5.8) | 23 (5.3) | 12 (7.3) | 12 (17.1) | 4 (16.7) | 8 (17.4) |
| Other single-agent chemotherapy | 108 (17.9) | 78 (17.9) | 30 (18.2) | 16 (22.9) | 7 (29.2) | 9 (19.6) |
| All other regimens | 65 (10.8) | 49 (11.2) | 165 (9.7) | 5 (7.1) | 2 (8.3) | 3 (6.5) |
1 L, first line; 2 L, second line; 3 L, third line; 4 L, fourth line.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
